Dr. Reddy's Laboratories Ltd. Share Price

DRREDDY get generic Semaglutide injection approval in Brazil

Dr. Reddy’s Laboratories Limited (NSE: DRREDDY) DRREDDY has received regulatory approval in Brazil for its generic Semaglutide injection, for adults with uncontrolled type 2 diabetes. The estimated addressable market for generic semaglutide in Brazil is $800 million. What happened: Dr. Reddy’s will launch with Aché, a Brazilian pharmaceutical manufacturer, under a co-commercialization partnership. Brazil follows earlier product filings in Canada and India. The company targets a combined supply of 6 million to 7 million semaglutide injector pens across key markets in H2 FY27. Why it matters: Brazil gives Dr. Reddy’s a large GLP-1 market where the company can sell. It also adds a growth line as older generics lose revenue after the loss of exclusivity on legacy oncology brands. My view: Treat $800 million as the size of the pool, not Dr. Reddy’s revenue. Approval is a permit. Sales depend on supply, and supply depends on the pen scale-up. The Q1 FY27 batch provision of ₹239.7 crore on semaglutide API shows what the ramp-up has cost so far. Aché brings local distribution and retail access, which cuts entry risk. Profit sharing terms are not disclosed, so margin impact is uncertain. Pricing will also come under pressure as more generic filers enter. What I am watching: the Brazil launch date with Aché, the Q3 relaunch of the Obeda brand, and whether pen supply tracks the H2 FY27 target. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.

Dr. Reddy's secures Brazil approval for semaglutide

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628 Dr. Reddy's Laboratories Limited ( DRREDDY ) has received marketing authorisation from Brazil's health regulator, ANVISA, for its generic semaglutide injection. The approval allows the company to expand its presence in the Latin American market. What happened? The product is indicated for adults with insufficiently controlled Type 2 diabetes and will be available as a pre-filled, multi-dose injectable pen in two presentations: 2 mg/1.5 mL and 4 mg/3 mL. It is designed for once-weekly administration. Dr. Reddy's plans to launch the product in Brazil in partnership with Aché. Brazil represents a significant potential market, with approximately 16.6 million adults aged 20–79 living with diabetes. The company's statement estimates the country's semaglutide market for diabetes at around $244.6 million. Why does it matter? The approval expands Dr. Reddy's semaglutide presence beyond India and strengthens its entry into a key Latin American market. It also marks regulatory progress after ANVISA rejected its earlier application in April 2026 over technical requirements. My view This approval is an important step in the company's global generics strategy. Semaglutide offers a potential growth opportunity, but commercial success will depend on launch execution, pricing, competition and the ability to maintain product quality and supply. What I am watching next I would track the Brazilian launch timeline, market penetration, pricing strategy, partnership execution and further regulatory approvals across international markets. No Recommendations Source: Business Standard Disclosure: I, my entity, associates or relatives do not have any holding, position or other material interest in Dr. Reddy's Laboratories Limited.

Dr Reddy’s gets USFDA nod for HIV prevention drug

Dr. Reddy’s Laboratories Limited has received tentative USFDA approval for its twice-yearly injectable lenacapavir for HIV prevention, covering 120 countries outside the US. The generic injection will be priced at $40 per person annually under its licensing agreement with Gilead Sciences. The approval covers HIV-1 pre-exposure prophylaxis (PrEP) for adults and adolescents weighing at least 35 kg. Dr. Reddy’s received the voluntary licence from Gilead in October 2024 and later partnered with Unitaid, Wits RHI and CHAI to accelerate development and regulatory approval. Initial supplies are expected before the end of 2026, followed by wider availability in 2027. My view: This approval strengthens Dr. Reddy’s position in complex generic injectables and opens access to a large international public health market. However, the $40 annual price makes scale, procurement volumes and manufacturing efficiency important for commercial returns. The opportunity is significant, but revenue contribution will depend on how quickly countries adopt the product. Investors should watch for initial supply orders, production ramp-up and commercial progress through 2027. Dr. Reddy’s shares traded at ₹1,352.90 on the NSE, up 0.81%. Stance: Positive from a business development perspective. Execution and actual order volumes will determine the financial impact. DRREDDY Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.

Nifty Outlook for 03-Nov-2026 looks Bullish

The Nifty 50 closed on Monday, November 2, 2026, with a strong surge of 1.68% at 23,440.80, hitting its intraday high of the session. The index cleared its 20-day and 50-day moving averages, fueled by heavyweights like Reliance Industries, Tata Steel, and broad-based sectoral participation. The Daily MACD Histogram is above zero and the Hourly MACD Histogram is also above zero indicating a bullish trend. The Daily RSI 14 at 61.03 above the midline 50 levels indicate a bullish trend and the Hourly RSI 14 is at the overbought territory above the 70 levels at 74.33 also indicate a bullish trend. But we may see a consolidation or a correction. Thus, the overall trend of Nifty looks bullish, and the buyers are in control over the markets. Buy on dips would be the best strategy to deploy for today’s market considering the overall trend of Nifty. We may expect a change in trend only if the price sustains below the support level. Can Initiate selling only if prices continue to sustain below the support level. I have provided Nifty Spot resistance and support levels which would help you learn in taking informed trading decisions using these levels and understand how support and resistance levels work in financial markets. Nifty Spot Resistance 1 - 23505 Resistance 2 - 23525 Support 1 - 23245 Support 2 - 23185 Happy Learning, Happy Trading and have a wonderful day Top Gainers : RELIANCE, JSWSTEEL, TATASTEEL. Top Losers : INFY, ICICIBANK, DRREDDY. RELIANCE

Dr. Reddy's Laboratories (NSE: DRREDDY) – Breakout Stock

DRREDDY Dr. Reddy's Laboratories (NSE: DRREDDY) – Breakout Stock for 28 October 2026 Latest price · 27 Oct, 3:28 PM ₹1,310.00 Day's range: ₹1,299.40–₹1,323.70 Breakout watch Source: Upstox market quote. Upstox - Online Stock and Share Trading Technical breakout analysis Dr. Reddy's witnessed strong buying on 26 October, gaining 6.62% with approximately 1 crore shares traded. Relative volume was nearly 3.93 times its 20-day average, indicating unusually high market participation. The stock was trading above its 50-day and 200-day moving averages, supporting a bullish technical structure. Dhan+1 Today's price action shows consolidation after the sharp rally, with ₹1,323.70 emerging as immediate resistance. Trading setup for tomorrow Parameter Indicative level Buy trigger Above ₹1,325 Target 1 ₹1,345 Target 2 ₹1,365 Target 3 ₹1,390 Stop-loss ₹1,298 Immediate support ₹1,300 These are proposed technical trading levels, not guaranteed targets. Trading strategy: Watch for a sustained 15-minute breakout above ₹1,325 accompanied by increasing volume. A successful breakout could open the way toward ₹1,345–₹1,365 in the short term. However, a decline below ₹1,298 would weaken the immediate bullish setup. Conclusion: Dr. Reddy's remains an interesting price-volume breakout candidate for 28 October. Prefer confirmation above resistance rather than buying into an unconfirmed opening spike. Research disclaimer: Educational technical analysis only. Trading involves market risk; use position sizing and independent assessment.

DR REDDY’S EYES FRESH GROWTH CYCLE ON SEMAGLUTIDE RELAUNCH

DRREDDY Dr Reddy’s Laboratories is preparing for a new phase of growth, driven by the planned relaunch of semaglutide in Canada, an expanding biosimilars pipeline, steady growth in its domestic business and the rapid expansion of its contract development and manufacturing organisation business, Aurigene Pharmaceutical Services. The company’s renewed growth strategy comes after disruptions in its semaglutide business and a sharp decline in revenue from the cancer drug lenalidomide. The company had regained momentum through new product launches, an improved product mix and tighter cost controls. These measures have helped the company’s EBITDA margin rise above 20 percent. The immediate growth trigger for Dr Reddy’s is the planned relaunch of semaglutide in Canada. Following manufacturing issues that led to a temporary withdrawal of the obesity and diabetes drug from the market, the company expects to resume supplies in November. Management has retained its target of supplying 6–7 million pens between November and March across 10 approved markets, with Canada expected to account for the majority of volumes. Dr Reddy’s has already secured approvals in 10 countries, including Canada and India. The company also sees significant long-term potential as registrations expand across Latin America, Africa and other emerging markets. The company has received US approval for rituximab, a cancer treatment that will be commercialised through its partner Fresenius Kabi. Meanwhile, abatacept, a drug used to treat autoimmune diseases, is emerging as a key growth opportunity in its biosimilars portfolio. The expansion of these products is expected to strengthen the company’s presence in specialised therapies and provide additional growth avenues beyond its existing portfolio.